Marcus Dijk - Mink Therapeutics Chief Officer
| INKT Stock | USD 0.68 0.01 1.49% |
Insider
Marcus Dijk is Chief Officer of Mink Therapeutics
| Age | 62 |
| Address | 149 Fifth Avenue, New York, NY, United States, 10010 |
| Phone | 212 994 8250 |
| Web | https://minktherapeutics.com |
Mink Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9725) % which means that it has lost $0.9725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.3898) %, meaning that it created substantial loss on money invested by shareholders. Mink Therapeutics' management efficiency ratios could be used to measure how well Mink Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 3.51 in 2024, whereas Return On Tangible Assets are likely to drop (5.18) in 2024. At this time, Mink Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 15.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 4.3 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Whitney Jones | Sangamo Therapeutics | N/A | |
| Sean Jeffries | Design Therapeutics | 44 | |
| Jason Amello | Candel Therapeutics | 56 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| LLM JD | Candel Therapeutics | 63 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Nathan Caffo | Candel Therapeutics | 55 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Pr Little | Affimed NV | N/A | |
| Bertrand Esq | Adaptimmune Therapeutics Plc | 57 | |
| Aron Feingold | Sangamo Therapeutics | N/A | |
| Andrew Ramelmeier | Sangamo Therapeutics | 62 | |
| ACA BA | Adaptimmune Therapeutics Plc | 54 | |
| Ann Leen | Allovir | 47 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Francesca MD | Candel Therapeutics | 46 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
Management Performance
| Return On Equity | -12.39 | ||||
| Return On Asset | -0.97 |
Mink Therapeutics Leadership Team
Elected by the shareholders, the Mink Therapeutics' board of directors comprises two types of representatives: Mink Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mink. The board's role is to monitor Mink Therapeutics' management team and ensure that shareholders' interests are well served. Mink Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mink Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kimberly Ha, Head Relations | ||
| Joy Zhou, Vice CMC | ||
| Garo Armen, Executive Chairman | ||
| Marcus Dijk, Chief Officer | ||
| Robert Foster, Director Affairs | ||
| Heather Boussios, General Officer | ||
| Jennifer Buell, CEO President | ||
| Christine Klaskin, Treasurer | ||
| Patrick MBA, VP Operations |
Mink Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mink Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.39 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 21.6 M | ||||
| Shares Outstanding | 39.54 M | ||||
| Shares Owned By Insiders | 74.66 % | ||||
| Shares Owned By Institutions | 2.30 % | ||||
| Number Of Shares Shorted | 48.63 K | ||||
| Price To Book | 10.05 X | ||||
| EBITDA | (22.72 M) | ||||
| Net Income | (22.46 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.